Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
307 people get VIVO articles and Market Currents by email alert.
Get email alerts on VIVO »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Business Wire (Mar 28, 2013)
-
-
Business Wire (Feb 6, 2013)
-
-
Business Wire (Jan 23, 2013)
-
Business Wire (Dec 13, 2012)
-
Business Wire (Dec 4, 2012)
-
Business Wire (Nov 28, 2012)
-
-
-
-
-
Business Wire (Sep 17, 2012)
-
To learn more about Seeking Alpha Pro, click here.
-
-
Meridian Bioscience Inc. Dividend Stock AnalysisDividends4Life • Mon, Mar 15, 2010 -
Meridian: A Timely Stock to ConsiderRobert Freedland • Mon, Nov 9, 2009 -
-
-
Meridian Bioscience UpdateRobert Freedland • Tue, Jul 22, 2008
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Update: 8 High-Growth Healthcare Stocks With Strong Sources Of ProfitabilityKapitall • Tue, Jul 17, 2012
-
-
-
-
-
Finding High-Yield Stocks With Major Growth ProspectsMyPlanIQ • Tue, Feb 7, 2012 -
There are no Transcripts on VIVO.
-
Business Wire (Mar 28, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Jan 23, 2013)
-
Business Wire (Dec 13, 2012)
-
Business Wire (Dec 4, 2012)
-
at CNBC.com (Nov 28, 2012)
-
Business Wire (Nov 28, 2012)
-
Business Wire (Sep 17, 2012)
-
Business Wire (Aug 28, 2012)
-
at Fox Business (Aug 14, 2012)
-
at Fox Business (Aug 14, 2012)
-
Business Wire (Jul 17, 2012)
-
Business Wire (Apr 12, 2012)
VIVO vs. ETF Alternatives
Company Description
Meridian is a fully-integrated life science company whose principal businesses are (i) the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain respiratory, gastrointestinal, viral and parasitic infectious diseases, (ii) the manufacture and distribution... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, April 25, 1:57 PM Meridian Bioscience, Inc. (VIVO) declares $0.19/share quarterly dividend, in line with previous. Forward yield 3.61%. For shareholders of record May 04. Payable May 14. Ex-div date May 01. (PR) Comment! [Dividends]
- Thursday, April 25, 11:35 AM Meridian Bioscience (VIVO): Q1 EPS of $0.24 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, April 25, 11:19 AM Meridian Biosciences (VIVO -5%) slides after reporting a mixed FQ2 this morning, with its EPS coming in at $0.24, in line with the Street, but revenue came in at $47.3M versus the estimated $49.66M. Sales were flat year over year. USDx sales increased by 7%, driven primarily by increases in C. difficile and foodborne test revenues. EURDx business unit sales -12%, due largely to continued weakness in European healthcare spending. Meridian Life Science revenue -8%. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, January 23, 7:36 AM Meridian Bioscience (VIVO): FQ1 EPS of $0.2 beats by $0.01. Revenue of $45.4M beats by $. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, December 13, 2012, 4:05 PM Meridian Bioscience (VIVO -1.4%) says it's successfully completed beta trials for two new illumigene molecular amplification tests. The assays are designed to specifically detect the DNA of Chlamydia trachomatis and Neisseria gonorrhoeae from both swab and urine samples. Comment! [Healthcare, On the Move]
- Tuesday, December 4, 2012, 10:23 AM Meridian Bioscience (VIVO) declares $0.19/share quarterly dividend, in line with previous. Forward yield 3.80%. For shareholders of record Dec. 14. Payable Dec. 24. Ex-div date Dec. 12. (PR) Comment! [Dividends]
- Thursday, November 8, 2012, 9:43 AM Meridian Bioscience, Inc. (VIVO) declares $0.19/share quarterly dividend, in line with previous. For shareholders of record Nov. 19. Payable Nov. 30. Ex-div Nov. 15. (PR) Comment! [Dividends]
- Thursday, November 8, 2012, 8:23 AM Meridian Bioscience (VIVO): Q3 EPS of $0.21 misses by $0.01. Revenue of $43.7M (+5.7% Y/Y) misses by $3M. (PR) Comment! [Earnings, Healthcare]
- Thursday, July 26, 2012, 10:55 AM Meridian Bioscience (VIVO): FQ3 EPS of $0.21 misses by $0.01. Revenue of $42.1M (+5% Y/Y) misses by $4.4M. (PR) Comment! [Earnings, Healthcare]
- Thursday, April 26, 2012, 10:51 AM Meridian Bioscience (VIVO): FQ2 EPS of $0.23 beats by $0.02. Revenue of $47.4M (+15.3% Y/Y) beats by $3M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, January 25, 2012, 5:40 PM Meridian Bioscience (VIVO -6.4%) had a rough day after reporting FQ1 revenue of $40.3M (+8% Y/Y) and EPS of $0.17, missing consensus by $3M and $0.02. The company notes its European diagnostic equipment business "continues to be a drag" on its performance, and that restructuring efforts "will take several more quarters to make a measurable difference." Comment! [Healthcare, Earnings, On the Move]
- Tuesday, December 27, 2011, 11:56 AM Meridian Bioscience (VIVO -0.4%) receives FDA clearance for a molecular diagnostics test for group B streptococcus. The firm says the new test will allow quicker identification of infections. Comment! [Healthcare]
- Thursday, November 10, 2011, 3:37 PM Meridian Bioscience (VIVO +2.6%) trades up despite its FQ4 earnings falling slightly short of analysts' estimates. Revenue rose a solid 16% Y/Y on an increase in European and global sales. The company also reaffirms FY12 guidance at the low end of its range, but in line with the Street's consensus view. Comment! [Healthcare, On the Move]
- Thursday, July 21, 2011, 9:45 AM More on Meridian Bioscience (VIVO -12%): Despite a double-digit increase in sales, margins fell on continued weakness from its European diagnostics and core life science units. On a local currency basis, European diagnostics revenue fell 6%, while core life science declined 12%. Comment! [Healthcare, On the Move]
- Thursday, July 21, 2011, 9:16 AM Meridian Bioscience (VIVO): Q3 EPS of $0.17 misses by $0.04. Sales of $40.1M (+18% Y/Y) misses by $3M. Revises down its fiscal 2011 guidance. (PR). Shares -12.5% premarket. Comment! [Healthcare, On the Move]
- Thursday, July 7, 2011, 3:21 PM Meridian Bioscience (VIVO +3.6%) gains on a Lazard upgrade. The firm cites improved FY12 sales visibility on its test menu for illumigene C. difficile - an infection that causes diarrhea - plus an expansion of the menu to include tests for Group B strep. Comment! [Healthcare, On the Move]